Drug Trial News

RSS

Novel combination treatment outperforms standard therapy in patients with EGFR NSCLC

The combination of the antibody amivantamab and lazertinib, a drug targeting EGFR, shows better clinical benefits compared to standard treatment in patients with advanced or metastatic non-small cell lung cancer with EGFR gene mutations who also present one of these poor prognosti markers: brain and/or liver metastases, p53 gene co-mutations, or the presence of circulating tumor DNA.

4 Jun 2024

SU2C-SARC032 trial: Immunotherapy reduces relapse risk in soft tissue sarcoma by 43%

For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues.

4 Jun 2024

Experimental treatment for metastatic pancreatic cancer shows promise in phase 2 clinical trial

Clinicians at Georgetown University's Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda).

3 Jun 2024

RNA-based therapy shows promise in reducing cholesterol and triglycerides

A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.

29 May 2024

$Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy$

Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after the successful development of a new alpha-ray therapeutic agent ([At-211] PSMA-5) and confirmation of its efficacy in animal models.

27 May 2024

SELECT trial shows semaglutide reduces kidney decline in obese patients

The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and established cardiovascular disease but without diabetes.

25 May 2024

Immunotherapy-chemotherapy combo boosts survival for patients with metastatic colorectal cancer

A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone.

24 May 2024

Phase 1 trial for EBC-129 progresses into dose expansion

The Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, is pleased to announce that the Phase 1 trial for EBC-129 has progressed into dose expansion.

24 May 2024

Donepezil fails to enhance cognitive abilities in breast cancer survivors: Phase III trial results

Many breast cancer survivors report cancer-related cognitive impairment following chemotherapy, although prevalence rates and severity vary.

20 May 2024

Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammation

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -; dupilumab -; that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report in the New England Journal of Medicine.

20 May 2024

Treating obesity using glucagon-like peptide-1-directed N-methyl-D-aspartate receptor inhibition

Bimodal drug that successfully cures obesity, hyperglycemia, and dyslipidemia in mouse models.

20 May 2024

Acetaminophen shows potential in preventing acute respiratory distress syndrome, organ injury in sepsis patients

A National Institutes of Health (NIH)-supported clinical trial has found that intravenous acetaminophen reduced sepsis patients' risk of having organ injury or developing acute respiratory distress syndrome, a serious condition that allows fluid to leak into the lungs.

20 May 2024

Vaccine candidate spurs elusive type of broadly neutralizing HIV antibodies

An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial.

17 May 2024

Varenicline shows promise in first U.S. trial for e-cigarette cessation

The first U.S. trial of varenicline for e-cigarette cessation shows promising results and warrants larger-scale trials, the researchers say.

17 May 2024

CONVINCE trial reveals the effect of long-term colchicine on recurrent stroke and cardiovascular events

In the international CONVINCE trial, presented today (15 May 2024) at the European Stroke Organisation Conference (ESOC) 2024, anti-inflammatory treatment with long-term colchicine did not reduce rates of recurrent stroke and cardiovascular events in patients with non-cardioembolic stroke in the primary intention-to-treat analysis.

16 May 2024

Investigational drug shows promise in increasing oxygen uptake for patients with heart condition

People with a common heart condition were able to use significantly more oxygen while exercising after taking an investigational drug in an international clinical trial, according to a study published today in the New England Journal of Medicine.

14 May 2024

Aficamten shows promise in enhancing exercise capacity in patients with hypertrophic cardiomyopathy

Even though mortality and hospitalization rates have improved, the quality of life for those living with hypertrophic cardiomyopathy (HCM) can be compromised with limiting symptoms such as exertional dyspnoea and decreased exercise capacity.

13 May 2024

CRISPR-based gene editing shows promise in treating rare form of blindness

About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine.

6 May 2024

MedStar Washington Hospital Center enrolls first U.S. patient in gene-editing therapy trial for heart disease

The first U.S. heart patient involved in a study for a new gene-editing therapy directly infused inside the body has successfully been enrolled at MedStar Washington Hospital Center.

6 May 2024

Plant-based medication may be an effective therapy to help people quit vaping

Eleven million U.S. adults use e-cigarettes to vape nicotine, and about half of them say that they want to stop, but many have trouble doing so because nicotine is an addictive drug.

6 May 2024

Previous
1
...
5
6
7
8
9
10
11
...
1143
Next

Drug Trial News

Novel combination treatment outperforms standard therapy in patients with EGFR NSCLC

SU2C-SARC032 trial: Immunotherapy reduces relapse risk in soft tissue sarcoma by 43%

Experimental treatment for metastatic pancreatic cancer shows promise in phase 2 clinical trial

RNA-based therapy shows promise in reducing cholesterol and triglycerides

Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy

SELECT trial shows semaglutide reduces kidney decline in obese patients

Immunotherapy-chemotherapy combo boosts survival for patients with metastatic colorectal cancer

Phase 1 trial for EBC-129 progresses into dose expansion

Donepezil fails to enhance cognitive abilities in breast cancer survivors: Phase III trial results

Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammation

Treating obesity using glucagon-like peptide-1-directed N-methyl-D-aspartate receptor inhibition

Acetaminophen shows potential in preventing acute respiratory distress syndrome, organ injury in sepsis patients

Vaccine candidate spurs elusive type of broadly neutralizing HIV antibodies

Varenicline shows promise in first U.S. trial for e-cigarette cessation

CONVINCE trial reveals the effect of long-term colchicine on recurrent stroke and cardiovascular events

Investigational drug shows promise in increasing oxygen uptake for patients with heart condition

Aficamten shows promise in enhancing exercise capacity in patients with hypertrophic cardiomyopathy

CRISPR-based gene editing shows promise in treating rare form of blindness

MedStar Washington Hospital Center enrolls first U.S. patient in gene-editing therapy trial for heart disease

Plant-based medication may be an effective therapy to help people quit vaping

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News